In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
CRA adds Harvard Business School Professor as Academic Affiliate to Antitrust & Competition Economics Practice
“I am pleased to welcome Feng to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He is a recognized expert on...